ArticleOncotarget2015
miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.Oncotarget · 2016Pooled it
- Review
- Therapeutic potential of synthetic microRNA mimics based on the miR-15/107 consensus sequence.Cancer gene therapy · 2025Article
- Microbiomes, Epigenomics, Immune Response, and Splicing Signatures Interplay: Potential Use of Combination of Regulatory Pathways as Targets for Malignant Mesothelioma.International journal of molecular sciences · 2022Review
- Dysregulation of microRNAs and tRNA-derived ncRNAs in mesothelial and mesothelioma cell lines after asbestiform fiber exposure.Scientific reports · 2022Article
- Promising therapeutic potential of tumor suppressor microRNAs for malignant pleural mesothelioma.Journal of cancer metastasis and treatment · 2022Article
- Development of a novel necroptosis-associated miRNA risk signature to evaluate the prognosis of colon cancer patients.Annals of translational medicine · 2021Article
- From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis.International journal of molecular sciences · 2021Review
- Recent Advances in miRNA Delivery Systems.Methods and protocols · 2021Article
- miR-193a Directly Targets PSEN1 and Inhibits Gastric Cancer Cell Growth, the Activation of PI3K/Akt Signaling Pathway, and the Epithelial-to-Mesenchymal Transition.Journal of oncology · 2021Article
- Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.Frontiers in oncology · 2021Review
- Downregulation of miR‑193a‑3p via targeting cyclin D1 in thyroid cancer.Molecular medicine reports · 2020Article
- Tumor Suppressor Role of hsa-miR-193a-3p and -5p in Cutaneous Melanoma.International journal of molecular sciences · 2020Article
- Inhibition of miR-18a-3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin.Oncology letters · 2020Article
- Manipulating microRNAs for the Treatment of Malignant Pleural Mesothelioma: Past, Present and Future.Frontiers in oncology · 2020Review
- miR-193a-3p Mediates Placenta Accreta Spectrum Development by Targeting EFNB2 via Epithelial-Mesenchymal Transition Pathway Under Decidua Defect Conditions.Frontiers in molecular biosciences · 2020Article
- Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma.Therapeutic advances in medical oncology · 2020Review
- Transcriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesothelioma.Oncotarget · 2019Article
- Circular RNA circHIPK3 promotes cell proliferation and invasion of prostate cancer by sponging miR-193a-3p and regulating MCL1 expression.Cancer management and research · 2019Article
- Knockdown long noncoding RNA nuclear paraspeckle assembly transcript 1 suppresses colorectal cancer through modulating miR-193a-3p/KRAS.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant pleural mesothelioma (MPM) is an asbestos-induced cancer with poor prognosis that displays characteristic alterations in microRNA expression. Recently it was reported that the expression of a subset of microRNAs can distinguish between MPM and adenocarcinoma of the lung. However, the functional importance of these changes has yet to be investigated. We compared expression of miR-192, miR-193a-3p and the miR-200 family in normal pleura and MPM tumor specimens and found a statistically significant reduction in the levels of miR-193a-3p (3.1-fold) and miR-192 (2.8-fold) in MPM. Transfection of MPM cells with a miR-193a-3p mimic resulted in inhibition of growth and an induction of apoptosis and necrosis in vitro. The growth inhibitory effects of miR-193a-3p were associated with a decrease in MCL1 expression and were recapitulated by RNAi-mediated MCL1 silencing. Targeted delivery of miR-193a-3p mimic using EDV minicells inhibited MPM xenograft tumour growth, and was associated with increased apoptosis. In conclusion, miR-193a-3p appears to have importance in the biology of MPM and may represent a target for therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.